Changes in Beneficial Ownership · 4
CG Oncology, Inc.
CGONNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-14
- Issuer
- CG Oncology, Inc.
- Issuer CIK
- 0001991792
- Trading symbol
- CGON
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- POST LEONARD E
- Reporting owner CIK
- 0001235862
- Relationship
- Director
- Address
- C/O CG ONCOLOGY, INC., 3000 PEGASUS PARK DRIVE, SUITE 1640, DALLAS, TX, 75247
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-14 | M · Form 4 | 1,000 | A | 0.6 | 1,000 | D |
| Common Stock | 2026-08-14 | S · Form 4[F1] | 1,000 | D | 74.54 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy) | 0.6 | 2026-08-14 | M · Form 4 | 1,000 | D | 0 | [F2] | 2028-07-08 | Common Stock | 1,000 | 104,077 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
Signature 1
- Signed
- /s/ Joshua F. Patterson, Attorney-in-Fact for Leonard Post
- Date
- 2026-08-18
Company context
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.